晚期非小细胞肺癌吉非替尼或厄洛替尼治疗失败后再次同药给予的疗效分析

摘要

Few treatment options are available for advanced non-small cell lung cancer. patients who have failed of gefitinib or erlotinib treatment in second/third-line treatment. The aim of this study was to evaluate the feasibility and safety of retreatment the same EGFR-tyrosine kinase inhibitor(EGFR-TKI) after the failure of gefitinib or erlotinib based on the data from our hospital. The clinical data of 33 patients with advanced NSCLC who were admitted to Zhejiang Cancer Hospital from January 2007 to July 2011 were retrospectively analyzed. All of the patients were given the same TKI treatment after the failure of gefitinib or erlotinib. Survival analysis was evaluated by Kaplan-Meier method.